Peptide InjectionsAI
Moderate evidence

Eloralintide

Peptide therapy: benefits, side effects, cost and protocols

C201H319N49O65S2

4,526 g/mol / CID 175663130
C201H319N49O65S2

Eloralintide is an investigational dual amylin and calcitonin receptor agonist being studied for weight management. It works by reducing appetite and slowing gastric emptying through amylin-pathway mechanisms that complement GLP-1-based therapies.

ByChris Riley(CFA)|Updated

Sources: FDA / PubMed / ClinicalTrials.gov View

FDA status
Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
Evidence
Moderate Evidence

How Eloralintide works

Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.

Key studies

10 papers on PubMed / 7 human trials

  1. 01

    Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

  2. 02

    Bhattachar S, Tham LS, Tidemann-Miller B et al

    Diabetes Obes Metab / Diabetes Obes Metab / Phase 1

  3. 03

    Eloralintide, a long-acting amylin agonist, shows proof of concept for obesity

  4. 04

    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

  5. 05

    Billings LK, Hsia S, Bays H et al

    Lancet / Phase 2

  6. 06

    Eloralintide demonstrates efficacy in obesity treatment in phase 2 randomized trial

  7. 07

    Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

  8. 08

    Briere DA, Qu H, Lansu K et al

    Mol Metab / Mol Metab

  9. 09

    Eloralintide, a novel amylin receptor agonist, shows potential for obesity treatment

Eloralintide compound data

C201H319N49O65S2
4526 g/mol
175663130 ↗
20-[[4-[[4-[[5-[[1-[2-[[2-[[4-amino-2-[[4-amino-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[5-amino-2-[[2-[[2-[2-[[20-[(4-amino-4-carboxy-butanoyl)amino]-17-(2-amino-2-oxo-ethyl)-8,14-bis(1-hydroxyethyl)-11-methyl-7,10,13,16,19-pentaoxo-1,3-dithia-6,9,12,15,18-pentazacyclohenicosane-5-carbonyl]amino]propanoylamino]-3-hydroxy-butanoyl]amino]acetyl]amino]pentanoyl]amino]-4-methyl-pentanoyl]amino]propanoylamino]-4-carboxy-butanoyl]amino]-2-methyl-3-phenyl-propanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-butanoyl]amino]-5-guanidino-pentanoyl]amino]-3-hydroxy-propanoyl]amino]-3-hydroxy-propanoyl]amino]-4-oxo-butanoyl]-methyl-amino]-4-oxo-butanoyl]amino]-3-phenyl-propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-6-[[1-[2-[2-[[1-[[1-[[1-[[2-[[2-[[3-amino-1-[[1-[[2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-2-methyl-propyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-3-methyl-butyl]amino]-6-oxo-hexyl]amino]-1-carboxy-4-oxo-butyl]amino]-1-carboxy-4-oxo-butyl]amino]-20-oxo-icosanoic acid

Eloralintide questions

What is ELORALINTIDE?

Eloralintide (LY3841136) is an investigational amylin receptor agonist being developed by Eli Lilly for weight management. It targets the amylin pathway, which is distinct from GLP-1 approaches.

How does ELORALINTIDE work?

Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.

Is ELORALINTIDE legal to buy?

ELORALINTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy ELORALINTIDE?

ELORALINTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does ELORALINTIDE belong to?

ELORALINTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of ELORALINTIDE?

ELORALINTIDE has been studied for: Weight loss potential, Appetite regulation via amylin pathway, Novel mechanism of action. Eli Lilly investigational compound. Targets amylin pathway distinct from GLP-1.

Eloralintide in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Eloralintide?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz